Global /United States /Healthcare /Biotechnology /XCUR

Exicure, Inc.

XCUR

• NASDAQ: XCUR • Delayed

3.31USD -4.6%

As of 15 June 2026, Exicure, Inc. has a market cap of $21.1M USD, ranking #36733 globally and #4973 in the United States. It ranks #3300 in the Healthcare sector, and #643 in the Biotechnology industry.

Global Rank

36733

Country Rank

4973

Sector Rank

3300

Industry Rank

643

Key Stats

Market Cap

$21.1MUSD

Enterprise Value

$18.55MUSD

EBITDA (TTM)

-$9.88MUSD

Net Income (TTM)

-$4.95MUSD

PB Ratio

5.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Jungsoo Kim open_in_new

Employees

Founded

2011

Website

exicuretx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.6%	-10%	-23%	-19%	-26%	-38%	-69%	-31%	-99%

News

XCUR Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	XCUR Exicure Inc ISIN: US30205M3097 Shares Out.: Shares Outstanding: 6.374M¹ Shares Float: 4.206M² TV: TradingView: NASDAQ: XCUR SA: Stock Analysis: NASDAQ: XCUR YF: Yahoo Finance: XCUR GF: Google Finance: NASDAQ: XCUR NQ: NASDAQ: XCUR BA: Barron's: XCUR MS: Morningstar: XNAS: XCUR	3.31 USD	TV: TradingView: NASDAQ: XCUR SA: Stock Analysis: NASDAQ: XCUR YF: Yahoo Finance: XCUR GF: Google Finance: NASDAQ: XCUR NQ: NASDAQ: XCUR BA: Barron's: XCUR MS: Morningstar: XNAS: XCUR

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Exicure, Inc.

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 865K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 758K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 131K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 125K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 119K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 86K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 227K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.92B 68.19T KRW 213K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.46B 60.27B AUD 201K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 200K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.17B 42.76T KRW 133K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 122K%	-	Germany

chevron_leftBack